

Nathalie Lassau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11084285/publications.pdf>

Version: 2024-02-01

80
papers

7,296
citations

94433

37
h-index

64796

79
g-index

85
all docs

85
docs citations

85
times ranked

7884
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker. <i>Cancers</i> , 2022, 14, 1337.	3.7	0
2	Lightweight U-Net For Lesion Segmentation In Ultrasound Images. , 2021, , .		7
3	New method for quantification of intratumoral heterogeneity: a feasibility study on Ktrans maps from preclinical DCE-MRI. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021, 34, 845-857.	2.0	2
4	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. <i>European Radiology</i> , 2021, 31, 6001-6012.	4.5	53
5	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2020 – WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. <i>Ultraschall in Der Medizin</i> , 2020, 41, 562-585.	1.5	130
6	Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver – Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 2579-2604.	1.5	210
7	Methodological Study to Investigate the Potential of Ultrasound-Based Elastography and Texture as Biomarkers to Monitor Liver Tumors. <i>Diagnostics</i> , 2020, 10, 811.	2.6	1
8	CT Texture Analysis Challenges: Influence of Acquisition and Reconstruction Parameters: A Comprehensive Review. <i>Diagnostics</i> , 2020, 10, 258.	2.6	27
9	Ultrasound Molecular Imaging of Renal Cell Carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles. <i>Scientific Reports</i> , 2020, 10, 7308.	3.3	18
10	Advanced Ultrasound Imaging for Patients in Oncology: DCE-US. <i>Recent Results in Cancer Research</i> , 2020, 216, 765-771.	1.8	1
11	Can we trust the calculation of texture indices of <sc>CT</sc> images? A phantom study. <i>Medical Physics</i> , 2018, 45, 1529-1536.	3.0	41
12	The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Long Version). <i>Ultraschall in Der Medizin</i> , 2018, 39, e2-e44.	1.5	627
13	How to perform Contrast-Enhanced Ultrasound (CEUS). <i>Ultrasound International Open</i> , 2018, 04, E2-E15.	0.6	222
14	A Novel Microflow Phantom Dedicated to Ultrasound Microvascular Measurements. <i>Ultrasonic Imaging</i> , 2018, 40, 325-338.	2.6	10
15	New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2171-2182.	1.5	31
16	Study of the reliability of quantification methods of dynamic contrast-enhanced ultrasonography: numerical modeling of blood flow in tumor microvascularization. <i>Physics in Medicine and Biology</i> , 2018, 63, 17NT01.	3.0	2
17	Study of Inpatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography. <i>Investigative Radiology</i> , 2017, 52, 148-154.	6.2	25
18	Toward a Standardization of Ultrasound Scanners for Dynamic Contrast-Enhanced Ultrasonography: Methodology and Phantoms. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2670-2677.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
20	Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-8.	0.8	1
21	Dynamic Contrast-Enhanced Ultrasound Parametric Maps to Evaluate Intratumoral Vascularization. <i>Investigative Radiology</i> , 2015, 50, 212-217.	6.2	44
22	Molecular Ultrasound Imaging Using Contrast Agents Targeting Endoglin, Vascular Endothelial Growth Factor Receptor 2 and Integrin. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 197-207.	1.5	28
23	Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors. <i>Investigative Radiology</i> , 2014, 49, 794-800.	6.2	121
24	Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. <i>Endocrine-Related Cancer</i> , 2014, 21, R105-R120.	3.1	59
25	Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. <i>European Urology</i> , 2014, 65, 766-777.	1.9	32
26	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. <i>Investigational New Drugs</i> , 2014, 32, 312-322.	2.6	6
27	Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 187-210.	1.5	652
28	Advanced Hepatocellular Carcinoma: Early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. <i>European Journal of Radiology</i> , 2013, 82, e205-e211.	2.6	88
29	Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombribulin (AVE8062) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 4832-4842.	7.0	43
30	Virtual Patients and Sensitivity Analysis of the Guyton Model of Blood Pressure Regulation: Towards Individualized Models of Whole-Body Physiology. <i>PLoS Computational Biology</i> , 2012, 8, e1002571.	3.2	23
31	Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine. <i>Future Oncology</i> , 2012, 8, 1215-1218.	2.4	13
32	Standardization of Dynamic Contrast-Enhanced Ultrasound for the Evaluation of Antiangiogenic Therapies. <i>Investigative Radiology</i> , 2012, 47, 711-716.	6.2	64
33	Assessment of Quantitative Perfusion Parameters by Dynamic Contrast-Enhanced Sonography Using a Deconvolution Method. <i>Journal of Ultrasound in Medicine</i> , 2012, 31, 595-608.	1.7	31
34	In vitro evaluation of the impact of ultrasound scanner settings and contrast bolus volume on time-intensity curves. <i>Ultrasonics</i> , 2012, 52, 12-19.	3.9	21
35	Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging. <i>Current Urology Reports</i> , 2012, 13, 70-81.	2.2	12
36	Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. <i>Investigational New Drugs</i> , 2012, 30, 144-156.	2.6	10

#	ARTICLE	IF	CITATIONS
37	Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. <i>Investigational New Drugs</i> , 2012, 30, 765-771.	2.6	57
38	Evaluation with DCE-US of antiangiogenic treatments in 539 patients allowing the selection of one surrogate marker correlated to overall survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4618-4618.	1.6	5
39	Impact of the arterial input function on microvascularization parameter measurements using dynamic contrast-enhanced ultrasonography. <i>World Journal of Radiology</i> , 2012, 4, 291.	1.1	10
40	Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2011, 4, 1.	1.8	24
41	Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantificationâ€™Preliminary Results. <i>Radiology</i> , 2011, 258, 291-300.	7.3	201
42	Estimation of intra-operator variability in perfusion parameter measurements using DCE-US. <i>World Journal of Radiology</i> , 2011, 3, 70.	1.1	36
43	Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. <i>Discovery Medicine</i> , 2011, 11, 18-24.	0.5	60
44	Imaging of perfusion using ultrasound. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 65-85.	6.4	160
45	Dynamic contrast-enhanced ultrasonography (DCE-US): a new tool for the early evaluation of antiangiogenic treatment. <i>Targeted Oncology</i> , 2010, 5, 53-58.	3.6	84
46	Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib) Tj ETQq0 0 0 rgBT /Overlock 10 New Drugs, 2010, 28, 199-202.	2.6	48
47	Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. <i>Investigational New Drugs</i> , 2010, 28, 690-693.	2.6	22
48	Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography. <i>Clinical Cancer Research</i> , 2010, 16, 1216-1225.	7.0	170
49	Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). <i>European Journal of Cancer</i> , 2010, 46, 1344-1351.	2.8	118
50	Acoustic characterization of a new trisacryl contrast agent. Part II: Flow phantom study and in vivo quantification. <i>Ultrasonics</i> , 2008, 48, 26-34.	3.9	2
51	A new functional imaging technique for the early functional evaluation of antiangiogenic treatment: dynamic contrast-enhanced ultrasonography (DCE-US). <i>Targeted Oncology</i> , 2008, 3, 111-117.	3.6	13
52	Acoustic characterization of a new trisacryl contrast agent. Part I: In vitro study. <i>Ultrasonics</i> , 2008, 48, 16-25.	3.9	8
53	Radiofrequency Thermal Ablation of Breast Cancer Local Recurrence: A Phase II Clinical Trial. <i>Annals of Surgical Oncology</i> , 2008, 15, 3222-3226.	1.5	24
54	Benefits of Contrast-Enhanced Sonography for the Detection of Liver Lesions: Comparison with Histologic Findings. <i>American Journal of Roentgenology</i> , 2008, 190, 683-690.	2.2	55

#	ARTICLE	IF	CITATIONS
55	Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography. <i>Investigative Radiology</i> , 2008, 43, 100-111.	6.2	72
56	Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. , 2008, , .		5
57	Imaging Medullary Thyroid Carcinoma with Persistent Elevated Calcitonin Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4185-4190.	3.6	246
58	Phase I Trial of Sorafenib in Combination with IFN α -2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 1801-1809.	7.0	136
59	Methodology for Quantifying Interactions Between Perfusion Evaluated by DCE-US and Hypoxia Throughout Tumor Growth. <i>Ultrasound in Medicine and Biology</i> , 2007, 33, 549-560.	1.5	39
60	Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. <i>European Radiology, Supplement</i> , 2007, 17, 89-98.	1.4	138
61	Imagerie de contraste ultrasonore pour l'évaluation précoce des thérapies ciblées. , 2007, , 81-86.		1
62	Gastrointestinal Stromal Tumors Treated with Imatinib: Monitoring Response with Contrast-Enhanced Sonography. <i>American Journal of Roentgenology</i> , 2006, 187, 1267-1273.	2.2	183
63	To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. <i>European Journal of Cancer</i> , 2006, 42, 2472-2479.	2.8	160
64	Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. <i>Cancer Imaging</i> , 2006, 6, 24-29.	2.8	68
65	Combination of HIFU therapy with contrast-enhanced sonography for quantitative assessment of therapeutic efficiency on tumor grafted mice. <i>Ultrasound in Medicine and Biology</i> , 2006, 32, 729-740.	1.5	23
66	Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 25-35.	1.6	1,088
67	Follow-up of Oncology Patients Undergoing Chemotherapy. , 2006, , 77-88.		3
68	In Vitro Echogenicity Characterization of Poly[lactide-coglycolide] (PLGA) Microparticles and Preliminary In Vivo Ultrasound Enhancement Study for Ultrasound Contrast Agent Application. <i>Investigative Radiology</i> , 2005, 40, 536-544.	6.2	15
69	In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts. <i>International Journal of Cancer</i> , 2005, 113, 881-890.	5.1	21
70	Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1717-1728.	4.1	89
71	Doppler US with perfusion software and contrast medium injection in the early evaluation of radiofrequency in breast cancer recurrences: A prospective phase II study. <i>European Journal of Radiology</i> , 2005, 56, 376-381.	2.6	23
72	Validation of a New Method for Quantifying In Vivo Murine Tumor Necrosis by Sonography. <i>Investigative Radiology</i> , 2004, 39, 350-356.	6.2	29

#	ARTICLE	IF	CITATIONS
73	Comparison of new ultrasound index with laser reference and viscosity indexes for erythrocyte aggregation quantification. <i>Ultrasound in Medicine and Biology</i> , 2003, 29, 789-799.	1.5	8
74	High-frequency sonography and color Doppler in the management of pigmented skin lesions. <i>Ultrasound in Medicine and Biology</i> , 2003, 29, 875-879.	1.5	48
75	Prognostic Value of Angiogenesis Evaluated with High-Frequency and Color Doppler Sonography for Preoperative Assessment of Melanomas. <i>American Journal of Roentgenology</i> , 2002, 178, 1547-1551.	2.2	77
76	A New Ultrasound Principle for Characterizing Erythrocyte Aggregation. <i>Investigative Radiology</i> , 2002, 37, 413-420.	6.2	8
77	Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease. <i>Transplantation</i> , 2002, 74, 60-66.	1.0	63
78	Evaluation of Contrast-Enhanced Color Doppler Ultrasound for the Quantification of Angiogenesis In Vivo. <i>Investigative Radiology</i> , 2001, 36, 50-55.	6.2	94
79	New Hemodynamic Approach to Angiogenesis. <i>Investigative Radiology</i> , 1999, 34, 194-198.	6.2	45
80	Radiologic Assessment of Intranodal Vascularity in Head and Neck Squamous Cell Carcinoma. <i>Investigative Radiology</i> , 1996, 31, 673-679.	6.2	20